Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40,201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.
Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, Li Y, Zhang L, Wang X, Li L, Lu J, Xu A, Yang S, Lu Y, Sun J, Li Z, Zhu X, Jiang M, Zhang S, Wang W, Li Y, Meng Z, Li H, Mou K, Han X, Li S, Chen A, Li X, Liu D, Zhang C, Ji C, Wang Y, Cheng H, Cui X, Yao X, Bai X, Dong G, Xu J. Yan K, et al. Among authors: li f, li s, li y, li z, li h, li x, li l. J Am Acad Dermatol. 2025 Jan;92(1):92-99. doi: 10.1016/j.jaad.2024.09.031. Epub 2024 Sep 26. J Am Acad Dermatol. 2025. PMID: 39332633 Clinical Trial.
Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.
Zhao Y, Zhang J, Yang B, Li J, Ding Y, Wu L, Zhang L, Wang J, Zhu X, Zhang F, Tao X, Li Y, Zhang C, Li L, Lu J, Diao Q, Lu Q, Man X, Li F, Xia X, Cheng H, Jia Y, Zhao G, Yan J, Chen B. Zhao Y, et al. Among authors: li f, li y, li j, li l. Chin Med J (Engl). 2024 Jan 20;137(2):200-208. doi: 10.1097/CM9.0000000000002747. Epub 2023 Jul 21. Chin Med J (Engl). 2024. PMID: 37482623 Free PMC article. Clinical Trial.
Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension.
Yu C, Geng S, Yang B, Deng Y, Li F, Kang X, Bi M, Zhang F, Zhao Y, Pan W, Tian Z, Xu J, Zhang Z, Yu N, Duan X, Guo S, Sun Q, Li W, Tao J, Liu Z, Yin Y, Wang G. Yu C, et al. Among authors: li f, li w. Chin Med J (Engl). 2024 May 20;137(10):1190-1198. doi: 10.1097/CM9.0000000000002873. Epub 2024 Jan 9. Chin Med J (Engl). 2024. PMID: 38192233 Free PMC article. Clinical Trial.
Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial.
Zhao Y, Li JY, Yang B, Ding YF, Wu LM, Zhang LT, Wang JY, Lu QJ, Zhang CL, Zhang FR, Zhu XH, Li YM, Tao XH, Diao QC, Li LF, Lu JY, Man XY, Li FQ, Xia XJ, Song JR, Jia YM, Zhang LB, Chen B, Zhang JZ. Zhao Y, et al. BioDrugs. 2024 Sep;38(5):681-689. doi: 10.1007/s40259-024-00668-z. Epub 2024 Jul 31. BioDrugs. 2024. PMID: 39080181 Clinical Trial.
Chinese expert consensus on management of antifungal-resistant dermatophytoses (2024 edition).
Liang G, Li X, Li R, Wen H, Gu J, Ran Y, Xi L, Li F, Zhang Q, Cao C, Feng P, Fu M, Jiang Y, Li S, Liu H, Liu Z, Lv X, Abliz P, Pan W, Sang H, She X, Shi D, Tong Z, Wang A, Wang L, Xiao Y, Yang J, Yang L, Yu J, Zhan P, Zhang S, Zhang Y, Zhu H, Zhu M, Song G, Kong X, Liu W. Liang G, et al. Among authors: li f, li s, li x, li r. Mycoses. 2024 Sep;67(9):e13785. doi: 10.1111/myc.13785. Mycoses. 2024. PMID: 39245647
40,201 results
You have reached the last available page of results. Please see the User Guide for more information.